Clinical trial · Interventional
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
Effects of Rice Bran on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer and Its Impact on the Quality of Life
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head &Amp; Neck Cancer | — | UNRESOLVED | — |
| Head &Amp; Neck Squamous Cell Carcinoma | — | UNRESOLVED | — |
| Radiation-Induced Oral Mucositis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rice bran | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Rice Bran Supplement Group
- description
- Participants in this group will receive rice bran supplements daily during their radiation therapy. The supplement is intended to reduce the severity of oral mucositis and improve quality of life.
- interventionNames
- Dietary Supplement: rice bran
- type
- NO_INTERVENTION
- label
- Control Group (Standard Care)
- description
- Participants in this group will receive standard care during radiation therapy without rice bran supplementation. Their oral mucositis symptoms and quality of life will be monitored for comparison.
Primary outcomes (1)
- measure
- Incidence of grade ≥ 3 mucositis .
- timeFrame
- From the start of radiation therapy until 2 weeks after completion of treatment (approximately 8 weeks)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patients of age 18 years old tor more * Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors. * Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2 * Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy * Ready to provide written informed consent Exclusion Criteria: * Receiving any other approved or investigational anti-cancer agent than those specified in this study. * Pregnant or breastfeeding female patients * Patients who have oral lesions unrelated to treatment or cancer, * Patients who are on drugs that could cause oral lesions or are using anticoagulants.
References
Publications (0)
Data not yet available